Delafloxacin-Loaded Poly(<scp>d</scp>,<scp>l</scp>-lactide-<i>co</i>-glycolide) Nanoparticles for Topical Ocular Use: <i>In Vitro</i> Characterization and Antimicrobial Activity

<b>Objective</b>: We developed delafloxacin (Dela)-loaded PLGA nanoparticles (PNPs) for potential ocular application <i>via</i> a topical route to treat eye infections caused by Gram-positive and Gram-negative bacteria. <b>Methodology</b>: Dela-PNPs were formulated using the emulsification-solvent evaporation method and stabilized using poly(vinyl alcohol) (PVA). Size and morphology were characterized by using dynamic light scattering (DLS) and scanning electron microscopy (SEM). Drug loading and encapsulation efficiency were measured <i>via</i> HPLC. Differential scanning calorimetry (DSC) and Fourier-transform infrared spectroscopy (FTIR) assessed the physical state and drug-polymer interaction. The <i>in vitro</i> drug release was evaluated using the dialysis bag method in simulated tear fluid (STF, pH 7.4) with Tween 80 (0.5%). The antimicrobial efficacy was determined by a minimum inhibitory concentration (MIC) and zone of inhibition tests against various bacteria. <b>Results</b>: Optimally sized PNPs were produced (238.9 ± 10.2 nm) with a PDI of 0.258 ± 0.084 and a ζ-potential of 2.78 ± 0.34 mV. Using 40 mg of PLGA, 4 mg of Dela, and 1% PVA, drug encapsulation and loading were 84.6 ± 7.3 and 12.9 ± 1.7%, respectively. DSC indicated that Dela was entrapped in an amorphous state within the PNPs. FTIR spectra showed no drug-polymer interactions. The formulation showed 40.6 ± 4.2% drug release within 24 h and 84.4 ± 6.1% by 96 h. MIC tests showed high susceptibility of <i>Streptococcus pneumoniae</i>, <i>Klebsiella pneumoniae</i>, and <i>Escherichia coli</i> (∼0.31 μg/mL) compared to <i>Staphylococcus aureus</i> and MRSA-6538 (∼0.63 μg/mL) and <i>Bacillus subtilis</i> (2.5 μg/mL). Stability studies showed minimal changes in particle characteristics over 3- and 6-month storage at 25 and 37 °C. <b>Conclusion</b>: Dela-PNPs exhibit significant potential as a nanoformulation for ocular applications.

Authors

Institutions

Publication Details

Journal
ACS Omega
Published
2024-12-12
DOI
https://doi.org/10.1021/acsomega.4c07805
Citations
5
Primary Topic
Advanced Drug Delivery Systems
Type
article
Field-Weighted Citation Impact
1.04

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Delafloxacin-Loaded Poly(d,l-lactide-co-glycolide) Nanoparticles for Topical Ocular Use: In Vitro Characterization and Antimicrobial Activity

Sulaiman S. Alhudaithi, Aliyah Almomen, Abdullah K. Alshememry, Raisuddin Ali et al.
5 citations
ACS Omega
Advanced Drug Delivery Systems
1.04
article

Delafloxacin-Loaded Poly(d,l-lactide-co-glycolide) Nanoparticles for Topical Ocular Use: In Vitro Characterization and Antimicrobial Activity

Sulaiman S. Alhudaithi, Aliyah Almomen, Abdullah K. Alshememry, Raisuddin Ali, Mudassar Shahid, Ziyad Binkhathlan, Mohd Abul Kalam, Nada A. Alshumaimeri, Ziyad A. BinHudhud, Abdulrazzaq A. Aldaham
article en
5 citations

Abstract

<b>Objective</b>: We developed delafloxacin (Dela)-loaded PLGA nanoparticles (PNPs) for potential ocular application <i>via</i> a topical route to treat eye infections caused by Gram-positive and Gram-negative bacteria. <b>Methodology</b>: Dela-PNPs were formulated using the emulsification-solvent evaporation method and stabilized using poly(vinyl alcohol) (PVA). Size and morphology were characterized by using dynamic light scattering (DLS) and scanning electron microscopy (SEM). Drug loading and encapsulation efficiency were measured <i>via</i> HPLC. Differential scanning calorimetry (DSC) and Fourier-transform infrared spectroscopy (FTIR) assessed the physical state and drug-polymer interaction. The <i>in vitro</i> drug release was evaluated using the dialysis bag method in simulated tear fluid (STF, pH 7.4) with Tween 80 (0.5%). The antimicrobial efficacy was determined by a minimum inhibitory concentration (MIC) and zone of inhibition tests against various bacteria. <b>Results</b>: Optimally sized PNPs were produced (238.9 ± 10.2 nm) with a PDI of 0.258 ± 0.084 and a ζ-potential of 2.78 ± 0.34 mV. Using 40 mg of PLGA, 4 mg of Dela, and 1% PVA, drug encapsulation and loading were 84.6 ± 7.3 and 12.9 ± 1.7%, respectively. DSC indicated that Dela was entrapped in an amorphous state within the PNPs. FTIR spectra showed no drug-polymer interactions. The formulation showed 40.6 ± 4.2% drug release within 24 h and 84.4 ± 6.1% by 96 h. MIC tests showed high susceptibility of <i>Streptococcus pneumoniae</i>, <i>Klebsiella pneumoniae</i>, and <i>Escherichia coli</i> (∼0.31 μg/mL) compared to <i>Staphylococcus aureus</i> and MRSA-6538 (∼0.63 μg/mL) and <i>Bacillus subtilis</i> (2.5 μg/mL). Stability studies showed minimal changes in particle characteristics over 3- and 6-month storage at 25 and 37 °C. <b>Conclusion</b>: Dela-PNPs exhibit significant potential as a nanoformulation for ocular applications.

ACS OmegaVol. 9(51)
King Saud University (SA), Al-Ghad International Health Sciences Colleges (SA)
Ministry of Education – Kingdom of Saudi Arabi
Openalex Percentile: Top 26%
Advanced Drug Delivery Systems
1.04
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.